In vitro core

体外核心

• 批准号: 10592382
• 负责人: F. Michael Hoffmann
• 金额: $ 62.16万
• 依托单位: UNIVERSITY OF WISCONSIN-MADISON
• 依托单位国家: 美国
• 财政年份: 2019
• 资助国家: 美国
• 起止时间: 2019-04-01 至 2025-03-31
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10592382
• 关键词: vitro; core

In Vitro Core Project Summary The overarching goal of the Wisconsin Antimicrobial Drug Discovery and Development Center is to develop therapeutic countermeasures to tackle the antimicrobial resistance crisis. To assist in achieving that goal, the In Vitro Core will use state-of-the-art acoustic liquid handling robotics to assay the fractionated extracts and compounds for antibacterial and antifungal activity, toxicity on human primary cells, and hemolysis of red blood cells. The Core will provide the projects with data from secondary screens on strains resistant to available antibiotics or a Candida auris strain resistant to all clinically available antifungals. /Relevance/ The In Vitro Core will provide the Center and the three Projects with critical data on the antimicrobial, antifungal and in vitro toxicity of new compounds so that the Center can develop new, broad spectrum antimicrobial agents.

体外核心技术 项目摘要 威斯康星州抗菌药物发现和开发中心的总体目标是 制定治疗对策，以应对抗菌素耐药性危机。协助实现以下目标 这一目标，体外核心将使用最先进的声学液体处理机器人来分析 抗菌、抗真菌活性及对人体原代细胞毒性的分级提取物和化合物 细胞，以及红细胞的溶血。核心将向项目提供次要数据 对现有抗生素耐药菌株或对临床ALL耐药的金黄色念珠菌菌株的筛选 现有的抗真菌药物。 /相关性/ 体外核心将为该中心和三个项目提供关于抗菌剂的关键数据， 新化合物的抗真菌和体外毒性，使该中心可以开发新的、广谱的 抗菌剂。